A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14266 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Eric Wenlong Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, Proteasome Inhibitors. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PCAB (prednisone, cyclophosphamide, doxorubicin, carmustine) is a single‐day regimen previously used for induction and now in relapsed/refractory multiple myeloma (RRMM). We retrospectively analysed the outcomes of 85 patients from five Australian centres. These included 30 patients (35.3%) who received PCAB with one additional agent (bortezomib most frequently). Median age of the patients was 65 years (37–80), with a median of four (1–8) prior lines of therapy. ORR was 37% (CR 4.9%). Median progression free survival and overall survival were 4.4 months (95% CI 3.5–6.7) and 7.4 months (95% CI 6.4–10.2), respectively. Extramedullary disease (EMD) was associated with shorter survival. Grade 3 or 4 cytopenia and febrile neutropenia occurred in 76.2% and 39.1%, respectively, with six (7.1%) treatment‐related mortalities. Median inpatient stay was 3.3 days/28‐day cycle (IQR 0.6–13), and for patients who died, a median of 20.2% of days alive were spent inpatient (IQR 6.4–39.1%). Three patients were successfully bridged to CAR T‐cell therapy using PCAB, despite being penta‐exposed and having EMD. PCAB may be considered as a useful salvage therapy amongst other polychemotherapy regimens in late relapse. Further studies is warranted to investigate and define its role as a bridging therapy to novel therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia.
- Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
- Department of Haematology, ACT Pathology, Canberra Health Services, Canberra, Australia.
- College of Health and Medicine, Australian National University, Canberra, Australia.
- Department of Haematology, Liverpool Hospital, Sydney, Australia.
- Department of Haematology, Concord Repatriation General Hospital, Sydney, Australia.
Zitieren
APA
Li, E. W., Jones, E., Bryant, C., King, T., Talaulikar, D., Ng, J. Y., Bryant, A., Ridha, Z., Doo, N. W., Menzies, A., Ling, S., Ho, S. J., Abadir, E., Vanguru, V., Joshua, D., & Ho, P. J. (2024). A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies. European Journal of Haematology. https://doi.org/10.1111/ejh.14266
Vancouver
Li EW, Jones E, Bryant C, King T, Talaulikar D, Ng JY, et al. A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies. European Journal of Haematology. 2024. doi:10.1111/ejh.14266
BibTeX
@article{Li2024,
author = {Li, Eric Wenlong and Jones, Esther and Bryant, Christian and King, Tracy and Talaulikar, Dipti and Ng, Jun Yen and Bryant, Adam and Ridha, Zainab and Doo, Nicole Wong and Menzies, Anna and Ling, Silvia and Ho, Shir Jing and Abadir, Edward and Vanguru, Vinay and Joshua, Douglas and Ho, P Joy},
title = {A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14266}
}
EUVIMED